Generic Sernivo Availability
Last updated on May 7, 2025.
Sernivo is a brand name of betamethasone topical, approved by the FDA in the following formulation(s):
SERNIVO (betamethasone dipropionate - spray;topical)
-
Manufacturer: PRIMUS PHARMS
Approval date: February 5, 2016
Strength(s): EQ 0.05% BASE/SPRAY [RLD]
Is there a generic version of Sernivo available?
No. There is currently no therapeutically equivalent version of Sernivo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sernivo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical formulations comprising a steroid
Patent 10,179,137
Issued: January 15, 2019
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): PROMIUS PHARMA LLCThe application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,364,485
Issued: June 14, 2016
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): DR. REDDY'S LABORATORIES LTD.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,433,630
Issued: September 6, 2016
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): Dr. Reddy's Laboratories Ltd.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,439,911
Issued: September 13, 2016
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): Dr. Reddy's Laboratories Ltd.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,655,907
Issued: May 23, 2017
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): Dr. Reddy's Laboratories Ltd.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,775,851
Issued: October 3, 2017
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): Dr. Reddy's Laboratories, Ltd.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
-
Topical formulations comprising a steroid
Patent 9,877,974
Issued: January 30, 2018
Inventor(s): Ubaidulla Udhumansha & Kandavilli Sateesh & Vairale Ajay Sunil & Wayne Jeffrey A. & Nalamothu Vijendra & Meghal Mistry & Pakunlu Refika Isil
Assignee(s): Dr. Reddy's Laboratories, Ltd.The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Patent expiration dates:
- August 31, 2030✓✓
- August 31, 2030
More about Sernivo (betamethasone topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: topical steroids
- Breastfeeding
- En español
Patient resources
Other brands
Diprolene, Diprosone, Valisone, Luxiq, ... +4 more
Professional resources
- Sernivo prescribing information
- Betamethasone, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Valerate (Topical) (AHFS Monograph)
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.